sirolimus TSC seizures
Selected indexed studies
- Epileptogenesis in tuberous sclerosis complex-related developmental and epileptic encephalopathy. (Brain, 2023) [PMID:36806388]
- Everolimus. (Recent Results Cancer Res, 2018) [PMID:30069763]
- Rapamycin for longevity: the pros, the cons, and future perspectives. (Front Aging, 2025) [PMID:40620657]
_Worker-drafted node — pending editorial review._
Connections
sirolimus TSC seizures is a side effect of
Sources
- Rapamycin for longevity: the pros, the cons, and future perspectives. (2025) pubmed
- Everolimus. (2018) pubmed
- Everolimus as adjunctive therapy for tuberous sclerosis complex-associated partial-onset seizures. (2019) pubmed
- Epileptogenesis in tuberous sclerosis complex-related developmental and epileptic encephalopathy. (2023) pubmed
- Tuberous sclerosis complex. (2018) pubmed
- Tuberous sclerosis complex. (2026) pubmed
- Sirolimus relieves seizures and neuropsychiatric symptoms via changes of microglial polarity in tuberous sclerosis complex model mice. (2022) pubmed
- Neurodevelopmental Outcomes From the PREVeNT Trial. (2025) pubmed
- Preventative treatment of tuberous sclerosis complex with sirolimus: Phase I safety and efficacy results. (2024) pubmed
- Effectiveness and safety of everolimus treatment in patients with tuberous sclerosis complex in real-world clinical practice. (2023) pubmed